Second Genome CEO Predicts Paradigm Shift With Microbiome Discovery

California biotech, which has backing from major pharmas, explains the application of its microbiome discovery platform to multiple disease types.

Video interview
Second Genome CEO Glenn Nedwin Talks to Emily Hayes

Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome Inc. CEO Glenn Nedwin predicted in an interview at Biotech Showcase.

Second Genome has a proprietary microbiome discovery platform that it is using to develop small molecules, peptide biologics and bacterial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip